Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial

Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial

Key Findings

Dornase alfa, when administered through nebulization, effectively reduced systemic inflammation in severe COVID-19 pneumonia patients, as shown by a 33% reduction in C-reactive protein (CRP) levels compared to standard care.

Practical Solutions

The use of dornase alfa led to a 63% increase in live discharge rates, higher lymphocyte counts, and reduced levels of circulating cf-DNA and D-dimer, indicating a potential improvement in patient outcomes.

Value

The trial demonstrates the benefit of cost-effective therapies targeting extracellular chromatin, providing a practical solution for reducing pathogenic inflammation in COVID-19 pneumonia.

Funding and Clinical Trial Number

Funding for the trial was provided by LifeArc, Breathing Matters, and The Francis Crick Institute. The clinical trial was registered under NCT04359654.

PMID:39009040 | DOI:10.7554/eLife.87030

Clinical Trials and Medical Practice

Clinical trials play a crucial role in developing safe and effective treatments. It’s essential to translate their benefits into everyday medical practice. DocSym, an AI-driven platform, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.

Streamlining Healthcare Operations

In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.

By using AI, clinics can enhance their workflows, improve patient outcomes, and reduce paper routine. Learn more about how we can help at aidevmd.com.